Literature DB >> 10923659

Correlation of intellectual impairment in Parkinson's disease with FDG PET scan.

J C Wu1, R Iacono, M Ayman, E Salmon, S D Lin, J Carlson, D Keator, A Lee, A Najafi, J Fallon.   

Abstract

This study investigated the relationship between regional glucose metabolism with intellectual impairment in patients with Parkinson's disease using statistical parametric mapping. Regional cerebral glucose metabolism using [18F]deoxyglucose (FDG) PET scans were performed on 10 patients with Parkinson's disease. We used the intellectual impairment score from the UPDRS. PET scans were analyzed with SPM96. Patients showed significant positive correlations with left limbic structures such as the cingulate gyrus, parahippocampal gyrus, and medial frontal gyrus. Patients showed significant negative correlations with associative neocortical posterior structures such as bilateral parietal and occipital gyrus. There were significant relationships between regional glucose metabolism and intellectual impairment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923659     DOI: 10.1097/00001756-200007140-00016

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  3 in total

Review 1.  Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson's disease.

Authors:  Shichun Peng; David Eidelberg; Yilong Ma
Journal:  Neurosci Bull       Date:  2014-09-28       Impact factor: 5.203

2.  [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor.

Authors:  S Breit; M Reimold; G Reischl; T Klockgether; U Wüllner
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

Review 3.  Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.

Authors:  Zuzana Walker; Federica Gandolfo; Stefania Orini; Valentina Garibotto; Federica Agosta; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Marina Boccardi; Daniele Altomare; Cristina Festari; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-19       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.